TrialCurveBREAKWATER: reconstructed Kaplan–Meier curves
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Nat Med. 2025 Jan 25;31(3):901–8. doi: 10.1038/s41591-024-03443-3 |
|---|---|
| DOI | 10.1038/s41591-024-03443-3 |
| Registry | NCT04607421 |
| Phase | Phase 3 |
| Conditions | Neoplasms |
| Interventions | Encorafenib, Cetuximab, Oxaliplatin, Irinotecan, Leucovorin, 5-FU |
| Sponsor | Pfizer |
| Enrolment | 841 |
| Source licence | Figure published under CC BY 4.0 |
Overall survival
From figure panel · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: EC + mFOLFOX6 not reached; SOC 14.6 months. Survival at 6 months: EC + mFOLFOX6 92%; SOC 87%. Hazard ratio EC + mFOLFOX6 vs SOC 0.46 (95% CI 0.31–0.68).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| EC + mFOLFOX6 | 236 | 40 | not reached |
| SOC | 243 | 73 | 14.6 |
- EC + mFOLFOX6 vs SOC: reconstructed HR 0.46 (95% CI 0.31–0.68)
Landmark survival (reconstructed)
| Time | EC + mFOLFOX6 | SOC |
|---|---|---|
| 6 mo | 92.2% | 87.2% |
| 12 mo | 79.9% | 66.3% |
| 18 mo | 67.9% | 41.6% |
Checks against the published figure
- SOC median: printed 14.6, reconstructed 14.6 pass
- EC + mFOLFOX6 events: printed 40, reconstructed 40 pass
- EC + mFOLFOX6 n: printed 236, reconstructed 236 pass
- SOC events: printed 72, reconstructed 73 pass
- SOC n: printed 243, reconstructed 243 pass
- hazard ratio (direction inferred): printed 0.47, reconstructed 0.461 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- XELOX + bevacizumab ± adoptive cell immunotherapy in colorectal cancer: Overall survival; Progression-free survival
- Cetuximab β + FOLFIRI in RAS/BRAF wild-type colorectal cancer: Overall survival; Progression-free survival (BIRC-assessed)
- SCOT: Disease-free survival; Overall survival; Survival after recurrence (SAR)
- Sequential vs upfront oxaliplatin in metastatic colorectal cancer: Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials